Technical Intelligence & Insights
Dive into our comprehensive technical reports covering the Pharma Healthcare sector. We analyze novel patents, catalytic processes, and cost-reduction strategies to streamline your commercial manufacturing.
Novel preparation method for Arotinolol Hydrochloride via CN112300149A. Achieves high purity and cost reduction in pharmaceutical intermediates manufacturing through one-pot coupling.
Novel omega-aminotransferase mutant enables high-yield sitagliptin intermediate production with 99% ee value and reduced solvent constraints for global supply chains.
Patent CN1111531C details a scalable xylene-based process for castanospermine esters, offering significant cost reduction in pharma manufacturing and enhanced supply reliability.
Patent CN110540975B reveals high-efficiency biocatalytic route for sitagliptin precursors, offering superior stereoselectivity and reduced environmental impact for pharma supply chains.
Patent CN112707919B introduces a graphene-supported copper catalyst for synthesizing 3-decarbamoyl cefuroxime acid, offering high purity and reduced phosphorus waste.
Patent CN116396950A reveals a novel carboxylesterase mutant for efficient (R)-3-cyclohexene-1-carboxylic acid production, offering superior stereoselectivity and scalable biocatalysis for API intermediates.
Patent CN100379733C reveals a high-yield synthesis for triazole antifungal intermediates. Discover cost-effective manufacturing and scalable supply chain solutions.
Patent CN104926802B details improved synthesis for neuraminic acid derivatives offering enhanced purity and operational efficiency for global pharmaceutical intermediate supply chains.
Patent CN111875591B details a green one-pot synthesis for benzopyrone intermediates using recyclable ionic liquids, offering significant cost and purity advantages for pharmaceutical manufacturing.
Advanced continuous flow synthesis for ethyl 6-oxo-8-chlorooctanoate. A key lipoic acid intermediate offering high yield, superior purity, and scalable manufacturing solutions.
Patent CN108659094A reveals efficient Mycoleptodiscin A synthesis. Enables cost reduction in fine chemical manufacturing and reliable supply chain for high-purity intermediates.
Patent CN111549008B reveals a novel AcATA mutant for sitagliptin intermediate synthesis, offering superior conversion rates and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN111549008B reveals a novel AcATA mutant for sitagliptin intermediates. Achieves 90% conversion with superior purity and reduced environmental impact for pharma supply chains.
Novel lipase mutant enhances Pregabalin intermediate synthesis efficiency and purity. Cost-effective biocatalytic solution for pharmaceutical manufacturing supply chains.
Patent CN111689881A reveals a catalytic sulfonation method for 4-chloro-2-fluoro-5-sulfamoylbenzoic acid, offering high purity and yield for reliable pharmaceutical intermediate supply chains.
Patent CN105734028A reveals mutant epoxide hydrolase for high-purity R-epichlorohydrin. Enhances stability and activity for reliable pharmaceutical intermediate supply chains.
Novel patent CN108659031A offers mild conditions for eribulin intermediate. Enhances supply chain reliability and reduces manufacturing costs for pharma partners.
Patent CN108026130B reveals enzyme mutant method for NMN. Low cost, high purity, scalable supply chain solution for global buyers.
Patent CN105602922A reveals efficient amidase catalysis for gabapentin intermediates. Achieve high purity and cost reduction in pharmaceutical intermediates manufacturing with scalable biocatalytic routes.
Patent CN111172213B reveals dual-enzyme tandem method for L-ABA. Offers cost reduction and supply chain reliability for pharma intermediates.